AURKA (Aurora Kinase A) Gene
Overview
Mermaid diagram (expand to render)
AURKA (Aurora Kinase A) encodes a serine/threonine kinase essential for mitotic entry, centrosome maturation, and spindle assembly["@giet2010"]. While primarily studied in cancer biology due to its frequent overexpression in tumors, AURKA also has important functions in post-mitotic [neurons](/entities/neurons), including roles in cilia function, neuronal polarity, and dendrite morphogenesis["@barr2007"]. Dysregulated AURKA may contribute to neurodegeneration through effects on cell cycle re-entry in neurons, a hallmark of several neurodegenerative diseases["@zhu2014"].
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | AURKA |
| Full Name | Aurora Kinase A |
| Chromosomal Location | 20q13.2 |
| NCBI Gene ID | [6790](https://www.ncbi.nlm.nih.gov/gene/6790) |
| OMIM | [603072](https://www.omim.org/entry/603072) |
| Ensembl ID | ENSG00000087586 |
| UniProt ID | [O14965](https://www.uniprot.org/uniprot/O14965) |
| Alias | AURA, BTAK, STK15, STK6 |
</div>
Protein Structure and Function
AURKA is a member of the Aurora family of serine/threonine kinases, which also includes AURKB (Aurora Kinase B) and AURKC (Aurora Kinase C)[@carmena2003]. The protein has a conserved kinase domain flanked by N-terminal regulatory regions and C-terminal degradation motifs.
Domain Architecture
- N-terminal domain: Regulatory region containing degradation motifs (A-box, D-box)
- Kinase domain: Catalytic domain with activation loop phosphorylation site
- C-terminal domain: D-box for APC/C-mediated degradation
Catalytic Activity
AURKA kinase activity is tightly regulated:
Autophosphorylation: T288 autophosphorylation activates the kinase
TPX2 binding: Binding to the target protein TPX2 enhances activity
Phosphorylation: PP1 and [PP2A](/entities/pp2a) phosphatases deactivate AURKA
Degradation: APC/C-mediated ubiquitination targets AURKA for proteasomal degradationExpression Pattern
AURKA shows high expression in proliferating cells, but is also expressed in certain post-mitotic tissues:
Brain Expression
In the nervous system, AURKA is expressed in:
- Neural progenitor cells: High expression during development
- Ependymal cells: Moderate expression in adult brain
- Certain neuronal populations: Lower but detectable in specific brain regions
The expression in mature neurons is typically low but can be upregulated under certain conditions, including cellular stress and disease states[@sardon2010].
Normal Cellular Functions
Mitosis Regulation
AURKA's canonical functions in dividing cells include[@marumoto2003]:
G2/M transition: Triggers mitotic entry through phosphorylation of CDC25B
Centrosome maturation: Recruits pericentriolar material to centrosomes
Spindle assembly: Promotes microtubule nucleation and spindle formation
Chromosome alignment: Ensures proper kinetochore-microtubule attachment
Cytokinesis: Functions in cell division through AURKB cooperationNeuronal Functions
In neurons, AURKA has additional specialized roles[@leroux2017]:
Cilia function: Regulates primary cilia formation and function in neuronal precursors
Neuronal polarity: Contributes to axon-dendrite specification
Dendrite morphogenesis: Controls dendritic branching and arborization
Synaptic development: Involved in synapse formation and plasticityRole in Neurodegeneration
Cell Cycle Re-entry Hypothesis
One of the leading theories in neurodegeneration is that neurons inappropriately re-enter the cell cycle, leading to apoptotic cell death[@herrup2007]. AURKA plays a central role in this process:
- Cell cycle markers: Elevated AURKA is observed in AD, PD, and Huntington's disease brains
- DNA synthesis: Some neurons show evidence of incomplete DNA replication
- Cyclin expression: Aberrant cyclin expression triggers cell cycle re-entry
Alzheimer's Disease
AURKA has been specifically implicated in Alzheimer's disease[@zhu2014a]:
- [Tau](/proteins/tau) phosphorylation: AURKA can phosphorylate tau at multiple sites
- Amyloid effects: [Aβ](/proteins/amyloid-beta) exposure can upregulate AURKA expression
- Neuronal cell cycle: AURKA activation precedes neuronal death in AD models
Parkinson's Disease
In Parkinson's disease models[@liu2015]:
- [Alpha-synuclein](/proteins/alpha-synuclein): AURKA interacts with alpha-synuclein aggregation
- Mitochondrial dysfunction: AURKA may affect mitochondrial dynamics
- Dopaminergic neurons: Specific vulnerability may involve AURKA dysregulation
Amyotrophic Lateral Sclerosis
ALS research suggests[@ranganathan2009]:
- Glial proliferation: AURKA in reactive [astrocytes](/entities/astrocytes)
- Motor neuron stress: Cell cycle activation in dying motor neurons
- Therapeutic targeting: AURKA inhibitors being explored
Therapeutic Targeting
Cancer Therapy
AURKA is a validated cancer target, with several inhibitors in clinical development[@cheung2011]:
| Drug | Company | Stage | Notes |
|------|---------|-------|-------|
| Alisertib (MLN8237) | Millennium/Takeda | Phase III | Oral selective inhibitor |
| VX-680 (Tozasertib) | Vertex | Discontinued | First-generation inhibitor |
| Danusertib | Novartis | Phase II | Pan-Aurora inhibitor |
Neurodegenerative Disease
AURKA modulation for neurodegeneration is speculative but intriguing:
- Inhibitor use: Could prevent inappropriate cell cycle re-entry
- Timing: Critical window may exist early in disease process
- Side effects: Systemic inhibition may cause mitotic toxicity
Genetic Variants
Cancer-Associated Variants
| Variant | Effect | Associated Cancer |
|---------|--------|------------------|
| F31I | Gain of function | Breast cancer |
| V57I | Moderate activity | Various |
| L210F | Amplification | Ovarian cancer |
Neurodegeneration Variants
While no direct disease-causing mutations are known, expression quantitative trait loci (eQTLs) may modify disease risk.
Chemical Inhibitors
- Alisertib: Highly selective AURKA inhibitor
- VX-689: Potent small molecule inhibitor
- ZM447439: Broader Aurora kinase inhibitor
- siRNA/shRNA: Knockdown constructs
- CRISPR-Cas9: Gene editing approaches
- Overexpression vectors: Wild-type and mutant constructs
Summary
AURKA is a serine/threonine kinase with essential functions in cell division and emerging roles in neuronal biology. While best known as a cancer target, AURKA dysregulation may contribute to neurodegenerative diseases through aberrant cell cycle re-entry in neurons. Further research is needed to determine whether AURKA modulation could have therapeutic benefits in neurodegeneration.
See Also
- [Cell Cycle Re-entry](/mechanisms/cell-cycle-arrest)
- [Mitosis](/mechanisms/mitosis)
- [Aurora Kinase B](/entities/aurora-kinase-b)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tau Phosphorylation](/mechanisms/tau-phosphorylation)
External Links
- [NCBI Gene: aurka](https://www.ncbi.nlm.nih.gov/gene/)
- [PubMed: aurka](https://pubmed.ncbi.nlm.nih.gov/?term=aurka+neurodegeneration)
References
[Giet et al, The Aurora kinase family in cell division (2010)](https://pubmed.ncbi.nlm.nih.gov/20182621/)
[Barr & Gergely, Aurora-A: the maker and breaker of spindle poles (2007)](https://pubmed.ncbi.nlm.nih.gov/17277769/)
[Zhu et al, Cell cycle re-entry in neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24898701/)
[Carmena & Earnshaw, The cellular geography of the aurora kinases (2003)](https://pubmed.ncbi.nlm.nih.gov/14661089/)
[Sardon et al, Aurora-A in adult neurons (2010)](https://pubmed.ncbi.nlm.nih.gov/20436283/)
[Marumoto et al, Aurora-A - a mitotic serine-threonine kinase (2003)](https://pubmed.ncbi.nlm.nih.gov/14636555/)
[Leroux et al, Aurora-A and cilia (2017)](https://pubmed.ncbi.nlm.nih.gov/28849704/)
[Herrup & Yang, Cell cycle regulation in post-mitotic neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17482544/)
[Zhu et al, Aurora kinase A in Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24898701/)
[Liu et al, Aurora-A and Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26289367/)
[Ranganathan et al, Cell cycle activation in ALS (2009)](https://pubmed.ncbi.nlm.nih.gov/19530482/)
[Cheung et al, Clinical development of Aurora kinase inhibitors (2011)](https://pubmed.ncbi.nlm.nih.gov/21900453/)Pathway Diagram
The following diagram shows the key molecular relationships involving AURKA Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)